抵克立得对2型糖尿病患者血液流变学和血小板聚集的影响  

EFFECTS OF TICLOPIDINE ON HEMORRHEOLOGY AND PLATELET AGGREGATION IN TYPE 2 DIABETES MELLITUS

作　　者：李益明[1] 段文澜[1] 李吟遒 沈一鸣 杨秀芳[1] 朱禧星[1] 

机构地区：[1]上海医科大学华山医院内分泌科

出　　处：《中国新药杂志》1999年第2期111-113,共3页Chinese Journal of New Drugs

摘　　要：目的：观察抵克立得对２型糖尿病患者的血液流变学和血小板聚集功能的影响。方法：４４例高血粘度的２型糖尿病患者口服抵克立得片２５０ｍｇ，ｑｄ，疗程２周。结果：男性患者高切率全血粘度和低切率全血粘度分别降低１１．１％和１７．０％，１ｍｉｎ血小板聚集率和最大血小板聚集率分别降低２３．７％和２７．３％；女性患者高切率全血粘度和低切率全血粘度分别降低９．８％和２０．６％，１ｍｉｎ血小板聚集率和最大血小板聚集率分别降低１８．９％和２０．５％；治疗中未见明显不良反应。OBJECTIVE:To observe the effects of ticlopidine on hemorrheology and platelet aggregation in type 2 diabetes mellitus.METHODS:44 patients with high blood viscosity were treated with ticlopidine in a dose of 250 mg daily for 14 days.RESULTS:In male patients,their high sheer and low sheer blood viscosity (HSBV and LSBV)were reduced by 11.1% and 17.0% respectively and their one minute and maximum platelet aggregation rate(1 MPAR and MPAR)were reduced by 23.7% and 27.3% respectively.The corresponding data for female patients were 9.8% and 20.6% for HSBV and LSBV,and 18.9% and 20.5% for 1 MPAR and MPAR respectively.No obvious ADRs were observed.CONCLUSION:This study demonstrated that the blood viscosity and platelet aggregation in type 2 diabetes mellitus patients may be significantly reduced by ticlopidine.

关 键 词：抵克立得 2型糖尿病 血粘度 血小板聚集率 

分 类 号：R587.105[医药卫生—内分泌] R977.15[医药卫生—内科学]